Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer
复制标题
DOI：
10.1093/annonc/mdf270
复制
发表时间：
2002-10-01
影响因子：
50.5
通讯作者：
Hossfeld, DK
中科院分区：
文献类型：
--
作者：
Laack, E;Köhler, A;Hossfeld, DK
背景：基质金属蛋白酶（MMP）-9和血管内皮生长因子（VEGF）是两种参与血管生成的蛋白质。在本研究中，我们探讨了预处理MMP-9和VEGF血清水平与临床病理参数和结果的患者与非小细胞肺癌（NSCLC）的关联：患者和方法：从1998年2月至1999年10月，预处理血清MMP-9和VEGF水平进行了分析，在118例患者的酶联免疫测定。诊断时，50例患者（42%）分期为早期疾病（I/II），27例患者（23%）为局部晚期（IIIA/IIIB），41例患者（35%）为转移性疾病（IV）。在118例患者中，72例肿瘤切除，46例接受吉西他滨和长春瑞滨联合化疗。结果：所有118例患者的中位生存期为602天。手术组72例中位生存期为972天，化疗组46例中位生存期为298天（P < 0.001）。患有I/II期疾病和MMP-9血清水平的切除患者
Background: Matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) are two proteins involved in angiogenesis. In the present study we investigated the association of pretreatment MMP-9 and VEGF serum levels with clinicopathological parameters and outcome in patients with non-small-cell lung cancer (NSCLC).Patients and methods: From February 1998 to October 1999, pretreatment serum levels of MMP-9 and VEGF were analysed in 118 patients with enzyme-linked immunoassays. At diagnosis 50 patients (42%) were staged as early disease (I/II), 27 patients (23%) as locally advanced (IIIA/IIIB), and 41 patients (35%) had metastatic disease (IV). In 72 of the 118 patients tumours were resected and 46 patients received combination chemotherapy with gemcitabine and vinorelbine.Results: The median survival of all 118 patients was 602 days. The 72 patients who had undergone surgery had a median survival of 972 days and the 46 patients who were treated with chemotherapy had a median survival of 298 days (P < 0.001). Resected patients with stage I/II disease and an MMP-9 serum level